Arabic Arabic English English French French German German
dark

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness Inc. is pleased to announce that it has formally submitted the clinical trial application to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

JPM Day 4: Battered Emergent Solutions Looks Ahead, Vir and Thermo Fisher

Next Post

2022 will see pharma target nutraceutical products to tap into consumer spending on preventative health

Related Posts
Total
0
Share